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In order to establish if neuropsychiatric systemic lupus erythematosus (NPSLE) can be identified by any characteristic other than
those used to diagnose the neuropsychiatric (NP) disease itself, we retrospectively reviewed 98 systemic lupus erythematosus (SLE)
patients followed over a mean period of 10 years. NPSLE was identified in 22 patients. Stroke and generalized seizures were the
most frequent NP manifestations. The NPSLE and non-NPSLE groups were similar with regard to demographic characteristics,
ACR criteria, serum autoantibodies, and frequency of hypertension and hypercholesterolemia. Of note, compared to the non-
NPSLE group, NPSLE was associated with a higher frequency of smoking (78 versus 26%), organ damage (73 versus 34%), and
cumulative mortality rate (14 versus 7%). The series of patients was further analysed according to the presence of antiphospholipid
syndrome (APS). Significantly, the interval between the onset of NP disease and SLE diagnosis was shorter in the APS− (0.3 ± 1
years) than in the APS+ (5±7 years) groups. Recurrence and/or persistence of NP events were only documented in the APS− group.
Overall cumulative mortality was highest in NPSLE and in APS+ patients with inadequate anticoagulation control, identifying an
aspect that requires improved vigilance and the development of novel therapeutic modalities.
1. Introduction
In the course of their disease, many patients with systemic
lupus erythematosus (SLE) develop neurologic and psychi-
atric symptoms. According to recent reviews neuropsychi-
atric (NP) disease occurs in as many as 30–56% of all SLE
patients [1, 2]. However, the diagnosis of neuropsychiatric
SLE (NPSLE) remains diﬃcult. In a prospective study, only
approximately one-fourth of NP events were attributed to
SLE [3]. In addition, the proportion of NP cases amongst
SLE patients may be overestimated because events such
as cognitive impairment, mood, anxiety disorders, and
headaches depend on assessing the subjective complaints of
patients and are very frequent in the general population.
The American College of Rheumatology (ACR) has listed
19 clinical entities that define NPSLE [4], but these do not
diﬀerentiate, in population-based studies, NPSLE patients
from non-SLE controls. The exclusion of headache, mild
mood disorders, anxiety, mild cognitive dysfunction, and
polyneuropathy without electrophysiological confirmation
decreases the frequency of NPSLE diagnosis by half and
increases the specificity of the ACR criteria from 46% to
93% [5]. NP events attributed to SLE occur mainly in the 6
months prior to, and in the first year following the diagnosis
of SLE. However, these may be observed as late as 15 years
after the initial diagnosis of SLE [6]. Although the life
expectancy of patients with SLE has significantly improved
over the past 50 years [7–10], NPSLE patients have a poorer
quality of life than non-NPSLE patients [3, 6].
There are no unequivocal clinical parameters or defini-
tive laboratory tests for the diagnosis of NPSLE. Anti-Sm
[11], antiribosomal P [12], and anti-N-methyl-D-aspartate
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receptor subunit antibodies [13–16] are associated but are
not specific for NPSLE. The recognition of the antiphos-
pholipid syndrome (APS) is critical for the institution of
appropriate therapy [1, 17], but it occurs in SLE patients with
or without NP disease. Neurological symptoms are signifi-
cant manifestations of APS, including the recently described
reversible posterior leucoencephalopathy syndrome [18],
and endothelial dysfunction is well documented in SLE and
APS [19]. Computed tomography (CT) does not recognize
the diﬀuse presentations that may be detected by brain
magnetic resonance imaging in the brains of NPSLE patients
[20, 21]. However, in the absence of other diagnostic criteria
the usefulness of MRI for the diagnosis of NPSLE is limited,
since the lesions it detects are observed in healthy individuals
[22] and in many SLE patients with no NP symptoms [23,
24]. MRI is the most useful for detecting and monitoring
vascular ischemic and demyelinating lesions. In the absence
of a diagnostic gold standard for NPSLE, it is essential
to exclude other possible causes of NP symptoms such as
infections, or metabolic disturbancies using a combination
of CSF analysis, imaging, and electroencephalography [1].
With the objective of establishing and defining character-
istics of NPSLE patients we have conducted a retrospective
analysis of a series of SLE patients currently attending an
Autoimmune Disease (AID) Unit. We describe the identifi-
cation of NPSLE patients with and without APS, followed by
their comparison to SLE patients with no NP disease (non-
NPSLE) taking into account demographic, laboratory, and
imaging features as well as organ damage and survival.
2. Patients andMethods
2.1. Patients. The Autoimmune Disease Unit (AID) at the
Hospital Curry Cabral in Lisbon, Portugal, is a referral centre
for SLE patients. Since the establishment of the unit in 1993,
the diagnosis of SLE was made in 163 patients of whom 11
died, 38 were lost to follow-up, and 43 were transferred to
other units (known to be alive). The present study includes
98 patients under current follow-up. All fulfil the 1997
revised American College of Rheumatology (ACR) criteria
for the diagnosis of SLE [25]. The date at which the fourth
SLE classification criterion has been observed is recorded as
the date of diagnosis. A patient was retrospectively identified
as having NPSLE based on clinical diagnosis, according to
the 1999 ACR-defined clinical entities and in the absence of
an underlying non-SLE disease [4]. The date of the initial
NP event was taken as date of diagnosis, and subsequent
and persistent NP events were recorded. None of the patients
are considered to have NPSLE had evidence of infections or
severe electrolyte imbalance. NP symptoms as side eﬀects of
drugs were also excluded. Smoking, systemic arterial hyper-
tension, and hypercholesterolemia were recorded at the time
of the first NP or nephritis event. All patients were clinically
evaluated at least twice per year, some as frequently as every
month. Details of the medical history and examination,
haematological, biochemical, and serologic variables related
to the assessment of SLE were analysed. Patients considered
to have APS fulfilled the Sydney classification criteria [26],
with at least one major clinical criteria (vascular thrombosis
and/or pregnancy morbidity) and tested positive for lupus
anticoagulant (LAC), anticardiolipin antibodies (ACA), and
anti-β2 glycoprotein I (β2-GPI) at least twice on two separate
occasions.
2.2. Laboratory Tests. Serologic tests were performed at the
Immunology Laboratory of Hospital Curry Cabral.
Antinuclear antibodies (ANA) were detected by indirect
immunofluorescence (IIF) using HEp-2 epithelial cells
as the substrate (American Type Culture Collection CCL
23). The serum dilution was 1/160, and a titre equal to or
greater than 1 : 160 (20 IU) was considered positive. The
specificity of the ANA, namely, SSA, Sm, ribonucleoprotein
(U1RNP), histone, nucleosome and ribosomal P proteins
was determined by immunoblot line assay. Serum samples
were diluted 1/10 for detection of antibodies against double
stranded DNA on Crithidia Luciliae. Positive results were
quantified by enzyme-linked immunosorbent assay (ELISA)
for IgG. ELISA assays were also used for the quantification
of IgM and IgG antibodies against anti-cardiolipin and
anti-β2-GPI antibodies, and patients with antibodies
(>20 MPL or GPL units) on two occasions, at least 12
weeks apart, were considered to be positive. To test for
the lupus anticoagulant, phospholipid-dependent assays
were performed at the Haemostasis Laboratory of Hospital
Curry Cabral. The diluted Russell viper venom time
(LAC Screen/LAC Confirm) was used together with Silica
clotting time (SCT) (with low and high concentration of
phospholipids). Prothrombin-time tests were performed to
monitor warfarin therapy, and the results were expressed
as international normalized ratios. Cerebrospinal fluid
(CSF) was analysed for cells, protein, oligoclonal banding,
Ziehl-Nielsen stain, and bacterial/mycobacterial culture.
PCR for JC virus was only performed since 2010.
2.3. Neuroimaging and Vascular Assessment. Assessment of
the neurological system included cerebral CT scan and
MRI, electroencephalography, nerve conduction studies, and
lumbar puncture (LP). The exams were performed as judged
appropriate by the attending physician according to the
neuropsychiatric deficit, on a case by case basis. In all
patients with strokes, echocardiograms and carotid Doppler
ultrasound allowed for exclusion of atheroembolic disease.
2.4. Scores. Global disease activity was quantified by the
SLE Disease Activity Index (SLEDAI) [27] and cumulative
organ damage through the Systemic Lupus International
Collaborating Clinics (SLICC)/ACR Damage Index (SDI)
[28]. The presence of organ damage was considered when
the SDI score was ≥1. Retrospective determination of both
scores has been validated [29, 30].
2.5. Statistics. Descriptive statistics were used for all variables
with percentages and mean ± standard deviation (SD).
The Student’ t and Mann-Whitney U tests were used
for analysing quantitative and conventional chi-square and
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Fisher for qualitative diﬀerences. A P value <0.05 was taken
to indicate statistical significance.
3. Results
3.1. SLE Patient Classification. Ninety eight patients cur-
rently followed for SLE at the AID Unit of the Curry
Cabral Hospital in Lisbon were diagnosed between 1993 and
2010 and followed up for a mean duration of 9 ± 5 years.
The patients were divided into two major groups, namely,
patients with and without SLE-related NP disease, according
to the presence of 1999 ACR-defined neurological clinical
entities [4]. The two groups are referred to as NPSLE and
non-NPSLE. Both groups were further divided into patients
with and without the antiphospholipid syndrome, referred
to as APS+ and APS−, respectively. Anti-cardiolipin, anti-
β2-GPI, or LAC was present in 43% of all SLE patients,
and the frequency was similar in NPSLE and non-NPSLE.
After exclusion of 3 patients in whom cerebral events were
the defined thrombotic phenomena, APS occurred in a
similar percentage of NPSLE and non-NPSLE patients (27
versus 26%). The non-NPSLE group was further divided
into patients with and without nephritis, and in each
of these subgroups were APS+ and APS− cases. Defining
characteristics of patients in all subgroups are shown in
Supplementary Data 1 (see SupplementaryMaterial available
online at doi:10.5402/2012/989218).
3.2. Identification of Patients with NPSLE Disease. NPSLE
disease was identified in 22 of the 98 SLE patients. The
clinical, brain MRI, and EMG findings that contributed
to the diagnosis of NPSLE are shown separately for APS−
and APS+ NPSLE patients in Tables 1(a) and 1(b), respec-
tively. NP manifestations included (in descending order of
frequency) cerebrovascular disease (7/22; 38%), generalized
seizures (6/22; 27%), major depression (4/22; 18%), severe
headache (4/22; 18%), peripheral neuropathy (4/22; 18%),
and in single patients (8%) severe cognitive dysfunction,
acute confusional state, and Guillain-Barre´ syndrome. Iso-
lated mild symptoms of headaches, anxiety, depression, or
cognitive impairment were not considered as SLE-associated
NP disease. Active lupus nephritis was present in three
patients but neither in these patients with kidney disease,
nor in other NPSLE patients were there evidences of other
possible causes of NP disease such as side eﬀects of drugs,
severe electrolyte imbalance, or uremia. One patient was on
regular and eﬃcient dialysis for five years when peripheral
neuropathy was diagnosed. Neuroimaging demonstrated a
cerebral infarct in those patients with a clinical diagnosis
of isolated ischemic stroke. Multiple focal lesions in the
deep white matter, hyper-intense in T2-weighted images,
and FLAIR were present in some patients with generalized
seizures and depression. In retrospect, since lumbar puncture
was only performed in five patients, infections of the brain
could not be rigorously excluded for most of the NPSLE
patients at the time of the NP event.
3.3. Comparison of APS+ and APS− NPSLE Patients. The two
groups were very similar except for two striking diﬀerences.
First, all six patients with generalized seizures were in the
APS− groups. Second, the interval between the initial NP
symptoms and the diagnosis of SLE was short (0.3 ± 1 year)
for APS− and much longer (6 ± 7 years) for APS+ patients.
Strokes, peripheral neuropathy, and the simultaneous occur-
rence of more than one initial NP event were observed with a
similar frequency in APS+ and APS− groups. There were no
obvious diﬀerences between the APS+ and APS− groups with
respect to demographic characteristics, the number and type
of ACR criteria (Supplementary Data 1), and cumulative
presence of autoantibodies in the serum (Supplementary
Data 2). Recurrent and persistent NP manifestations such
as severe headache, depression, and/or confusion were
exclusively seen in four patients in the APS− group. Two
of these patients with recurrent NP symptoms also had
recurrent lupus nephritis and another had significant de novo
proteinuria (Supplementary Data 3). In these patients the
findings in repeated MRI scans remained unchanged. Details
of therapy are provided in Supplementary data 1 and 3.
3.4. Comparison of NPSLE and Non-NPSLE Patients. NPSLE
and non-NPSLE patients were compared with regard to
demographic characteristics (gender, age, ethnicity, country
of origin, marital status, progeny, and postsecondary edu-
cation), duration of disease and follow-up, ACR criteria,
laboratory findings, lupus disease activity, risk factors for
cardiovascular disease, organ damage, and survival.
3.4.1. Demographic Characteristics, Disease Duration, and
Follow-up. The demographic characteristics were very sim-
ilar in the NPSLE and non-NPSLE groups (Table 2). Patients
were predominantly women, Caucasian, born in Portugal,
had a similar mean age of disease onset (44± 12 and 45± 14
years), an almost identical disease duration (13 ± 7 and
13 ± 8 years), and mean follow-up (10 ± 5 and 9 ± 5 years),
respectively.
3.4.2. ACR Criteria and Autoantibodies Not Included in the
ACR Criteria. The NPSLE and non-NPSLE groups were very
similar with regard to the number of ACR criteria as well
as the type of ACR criteria (Table 3). The most frequent
ACR criteria in both groups were arthritis, malar rash,
photosensitivity, antinuclear, anti-dsDNA, and antiphospho-
lipid antibodies. Antibodies against SSA, ribonucleoprotein,
and histone were observed with similar frequencies in both
patient groups (data not shown). In particular, antiribosomal
P antibodies do not distinguish between both groups (the
frequencies in NPSLE and non-NPSLE were 24 and 16%
respectively, and this diﬀerence is not statistically signifi-
cant).
3.4.3. Lupus Disease Activity. In order to compare SLEDAI
scores between NPSLE (at the time of the inaugural NP
event) and non-NPSLE patients, we chose the group of
non-NPSLE nephritis patients for whom it was possible to
retrospectively calculate the score, at the time of nephritis
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Table 1: (a) Clinical, imaging, EMG, and EEG characteristics of individual APS− NPSLE patients recorded at the time of the initial NP
manifestation. (b) Clinical, imaging, EMG, and EEG characteristics of individual APS+ NPSLE patients recorded at the time of the initial NP
manifestation.
(a)
ID
Age of the patient at the
time of NP event (years)
Interval between NP event
and SLE diagnosis (years)
Case definition Brain CT scan/brain MRI/EMG
1∗ 16 −2
Generalized seizure
disorder, acute psychosis,
and severe hemicraneal
headache
MRI: generalized cortical atrophy
2 11 0
Generalized seizure
disorder
Not available
3∗ 30 0
Generalized seizure
disorder
MRI: multiple focal deep white matter lesions
hyperintense in T2-weighted images and
FLAIR
4∗ 17 0
Generalized seizure
disorder
MRI: no abnormality
5∗ 42 −1
Generalized seizure
disorder, severe headache,
major depression
MRI: subcortical high signal bifrontal, bilateral
deep cortical, and corona radiata focal lesions
in T2-weighted images.
6∗ 23 0
Generalized seizure
disorder and ischemic
stroke
MRI: right cerebral atrophy. Left thalamic
calcified lesion.
7 49 0 Ischemic stroke CT scan: ischemic infarct left hippocampus
8 31 1 Ischemic stroke CT scan: left lenticular haemorrhagic infarct
9 50 2 Ischemic stroke MRI: right ischemic parieto-temporal infarct
10 23 0 Peripheral neuropathy EMG: motor-sensitive neuropathy
11 17 1 Peripheral neuropathy EMG: motor-sensitive neuropathy
12∗ 45 0
Major depression, severe
hemicraneal headache
MRI: multiple focal deep white matter high
signal on T2-weighted images and FLAIR.
Small focal lesions in the subcortical fronto
parietal white matter, predominantly on the
right.
13∗ 29 2
Major depression with
suicidal ideation, cluster
headache
MRI: multiple small focal subcortical white
matter and right paramedian pontine
high-signal lesions on T2-weighted images and
FLAIR.
∗
Interictal EEG was performed in these patients. An epileptiform focus was detected in 3 (patients 3, 4, and 6) with no abnormality in the other 4 patients
(patients 1, 5, 12, and 13). Nephritis was present in patients 3, 12, and 13 at the time of the NP event.
(b)
ID
Age of the patient at the
time of NP event (years)
Interval between NP event
and SLE diagnosis (years)
ACR clinical entity
APS defining
event
Brain CT scan/brain MRI/EMG
14 29 5
Ischemic stroke
with hemorrhagic
transformation
Cerebral
thrombosis
MRI: subcortical right parietal ischemic
infarct with hemorrhagic transformation
15 34 17 Ischemic stroke
Peripheral
artery
thrombosis
MRI: right parietal ischemic infarct
16 43 0
Ischemic stroke
and 7 days later
Guillain Barre´
Syndrome
Cerebral
thrombosis
MRI: oval-shaped left subcortical
paraventricular high-signal lesions on T2-
and FLAIR-weighted images with a signal
change in diﬀusion sequence and a left
corona hemorrhagic infarct; EMG:
motor-sensitive polyneuropathy
17 34 1
Peripheral
neuropathy
Coronary
thrombosis
EMG: motor-sensitive neuropathy
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(b) Continued.
ID
Age of the patient at the
time of NP event (years)
Interval between NP event
and SLE diagnosis (years)
ACR clinical entity
APS defining
event
Brain CT scan/brain MRI/EMG
18 33 16
Peripheral
neuropathy
Repeated
dialysis access
thrombosis
EMG: motor-sensitive neuropathy
19 38 −2
Major depression;
ischemic optic
neuropathy,
Retinal artery
thrombosis
MRI: no abnormality
20∗ 43 14 Major depression
Limb deep
vein
thrombosis
and obstetric
loss
MRI: multiple focal subcortical lesions
hyperintense in T2
21 28 0
Migrainous
headaches and
acute confusional
state
Cerebral
thrombosis
MRI: no abnormality
22∗ 35 14
Severe headaches
and cognitive
dysfunction
Obstetric loss
MRI: multiple focal deep white matter
lesions hyperintense in T2 on
T2-weighted images and FLAIR.
∗
Interictal EEG was performed in 2 patients (patients 20 and 22). Left temporal subclinical rhythmic electrographic discharges of adults—SREDA was
detected in patient 22.
Table 2: Demographic characteristics, disease duration, and fol-
lowup of NPSLE and non-NPSLE patients.
Characteristics NPSLE
N (%)
Non-NPSLE
N (%)
Female 18 (82) 70 (92)
Male 4 (18) 6 (8)
Female :male ratio 4,5 11,7
Age, mean ± SD (y) 44± 12 45± 14
Caucasian 17 (77) 68 (89)
Non-Caucasian 5 (23) 8 (11)
Portugal 18 (82) 66 (87)
Portuguese speaking Africa 4 (18) 8 (11)
Brazil 0 2 (3)
Single 9 (41) 30 (39)
Nonsingle 13 (59) 46 (61)
Progeny 6 (27) 41 (54)
Postsecondary education 8 (36) 33 (43)
Disease duration, mean ± SD (years) 13± 7 13± 8
Followup, mean ± SD (years) 10± 5 9± 5
presentation. The mean SLEDAI values were 15 ± 10 in
NPSLE and 10 ± 4 in the isolated nephritis group. However,
when the SLEDAI values were calculated for the NPSLE
group without the NP component scores, the mean value
became 6 ± 4 indicating low generalized disease activity in
this group (data not shown).
3.4.4. Cardiovascular Risk Factors. The frequency of patients
who smoked was determined at the time of the defining
Table 3: ACR criteria in NPSLE and non-NPSLE patients.
ACR criteria
NPSLE
N (%)
Non-NPSLE
N (%)
Malar rash 14 (64) 29 (38)
Discoid rash 6 (27) 8 (11)
Photosensitivity 11 (50) 31 (41)
Oral ulcer 5 (23) 20 (26)
Arthritis 16 (73) 51 (67)
Serositis 2 (9) 11 (14)
Renal disorder 8 (36) 26 (34)
Haemolytic anemia 1 (5) 18 (24)
Lymphopenia 6 (27) 24 (32)
Thrombocytopenia 4 (18) 16 (21)
Antinuclear antibody 21 (95) 76 (100)
Anti-dsDNA antibodies 15 (68) 63 (83)
Anti-Sm antibodies 6 (27) 17 (22)
Anti-cardiolipin
antibodies/anti-β2GPI/Lupus
anticoagulant
9 (41) 33 (43)
Number of ACR criteria, mean ± SD 6± 2 5± 1
NP event, nephritis diagnosis or SLE diagnosis in the non-
NPSLE, nonnephritis patients. Smokers were significantly
more frequent in the NPSLE group (78%, n = 15) when
compared to non-NPSLE (26%, n = 20), and this diﬀerence
were statistically significant (P = 0, 001). Hypertension
and hypercholesterolemia was present in the lupus nephritis
group at a frequency of 65% each. These risk factors were
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Table 4: Initial and final SLICC scores in NPSLE and non-NPSLE
patients.
Characteristics NPSLE Non-NPSLE
Total number of patients 22 76
Total followup, mean ± SD 10± 5 9± 5
Number and % of patients with
organ damage (SDI ≥ 1) 16 (73) 17 (34)
Initial SDI, mean ± SD 0,44 ± 0,89 0
Final SDI, mean ± SD 2,31 ± 1,25 1,53 ± 0,80
Delta SDI, mean ± SD 1,88 ± 1,15 1,53 ± 0,80
found at a similar frequency in the NPSLE (23 and 22%,
resp.) and non-NPSLE nonnephritis groups (28 and 22%).
3.4.5. Organ Damage. Pathologies known to be caused by the
treatment with steroids (such as osteonecrosis, osteoporotic
fractures, cataracts, and hyperglycaemia) and neoplasia
occurred in both groups. Cumulative organ damage was
quantified as the Systemic Lupus International Collaboration
Clinics/ACR Damage Index (SDI). Organ damage as indi-
cated by SDI values ≥ 1 was observed in 73% of NPSLE
and in 34% of non-NPSLE patients (Table 4). This diﬀerence
is statistically significant (P = 0, 0001) and largely due to
the damage of the neurologic system that is evident in 14
of the 22 NPSLE patients, but absent in all non-NPSLE
patients. The diﬀerence between final and initial SDI scores
was, however, not significantly diﬀerent between the two
groups. Scores increased with the duration of the disease
in both groups and tended to be higher in NPSLE patients
(Figure 1).
3.4.6. Mortality. The cumulative mortality is shown in
Figure 2 for all SLE patients as well as for the NP and non-
NPSLE groups, and the causes of death are shown in detail in
Supplementary Data 4. Mortality was highest in the NPSLE
group, but the diﬀerence to the non-NPSLE group was not
statistically significant. Eleven patients died over an eighteen-
year follow-up. The average disease duration of the patients
who died was 13 ± 5 years. Six of the patients who died
had NPSLE, of which 4 fulfilled the criteria for APS. The 6
patients who were positive for antiphospholipid antibodies
died at a younger age (40 ± 13 versus 64 ± 8) (P = 0, 04).
Of note, 3 patients had an infratherapeutic INR at the time
of the thrombotic event that caused death, only one patient
died of an infection, and one patient died of cancer. None of
the patients died from renal failure.
4. Discussion and Conclusions
The objective of this work was to find features beyond
those associated with the clinical diagnosis of NPSLE that
may characterize this subgroup of patients. We report a
detailed description of 22 patients with NP manifestations
corresponding to 23% of our SLE patients under current
follow-up. This frequency is within the range of 12 to
30% previously reported in Portuguese series [31, 32]. In
0
1
2
3
4
5
SL
IC
C
 s
co
re
≤1 >1≤5 >5≤10
Disease duration (years) and total number of patients
>10≤15 >15≤20 >20
(N = 4) (N = 15) (N = 19) (N = 23) (N = 19) (N = 18)
NP   nNPNP   nNP NP   nNP NP   nNP NP   nNP NP   nNP
Figure 1: Final SLICC scores according to duration of follow-up in
NPSLE (NP) and non-NPSLE (nNP) patients.
0
20
40
60
80
100
120
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11C
u
m
u
la
ti
ve
 n
u
m
be
r 
of
 p
at
ie
n
ts
 
Overall (initial N = 109)
NPSLE (initial N = 27)
Non-NPSLE (initial N = 82)
Figure 2: Cumulative mortality shown for all SLE patients and for
each patient group (NPSLE and non-NPSLE). During follow-up, 5
NPSLE patients and 6 non-NPSLE patients died.
addition, this group of patients was not diﬀerent from
large, previously studied cohorts with regard to cumulative
clinical manifestations [33–36], frequency of anti-cardiolipin
antibodies [37, 38], and APS [39]. We also failed to find
significant diﬀerences between NPSLE and non-NPSLE with
regard to demographic features, the age at which SLE was
diagnosed, the disease duration, and follow-up time, in spite
of previous reports that NPSLE is less frequent in Caucasians
[3].
There was no significant diﬀerence between the NPSLE
and non-NPSLE groups in the frequency of skin lesions such
as malar rash, discoid lesions, photosensitivity, and in the
occurrence of isolated discoid lupus before SLE diagnosis.
Once again, these findings are in accordance with previous
observations in a prospective study of a large NPSLE cohort
[40] and in several other studies [1]. Likewise, no tests
for circulating antibodies were diﬀerentially found in our
patients with NPSLE. In particular, we found antiribosomal
P antibodies in both NPSLE (36%) and non-NPSLE patients
(33%). The association between these antibodies and NP
disease in SLE patient has been controversial [41–43], but a
recent meta-analysis concluded that circulating antiriboso-
mal P antibodies do not predict nor confirm the occurrence
of NP disease in SLE patient [12].
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Smoking aggravates end stage renal disease in lupus
nephritis [44], decreases the eﬃcacy of antimalarial agents in
cutaneous lupus [45], and contributes to arterial thrombotic
events, in particular in patients with antiphospholipid
antibodies [46]. Our finding that the proportion of smokers
was significantly higher in patients with NPSLE suggests that
smoking may also contribute to the development of the NP
disease in SLE patients.
Lupus disease activity was higher in the NPSLE group.
However, when the activity scores related to the NP disease
were excluded the SLEDAI was not significantly diﬀerent in
patients with and without NP disease. Generalized high SLE
disease activity is considered to be a risk factor for NPSLE
[1], but this may be overestimated by the fact that scoring
systems attribute a high score to NP symptoms and signs.
In accordance with a previous study [47] we did find more
organ damage in the NPSLE group which was, as expected,
due to neurological disease.
Significantly, we found that a heterogeneous group of
APS− NPSLE patients could be distinguished from the APS
positive group by the duration of SLE disease that preceded
the NP event. According to the original ACR criteria, NP
manifestations can precede the onset of lupus or occur at
any time during its course, in both active SLE and quiescent
periods, but a NP event is considered more likely to be
SLE related if it has not preceded the diagnosis of SLE by
more than 6 months [1, 3]. Ischemic stroke and generalized
seizures were the most frequent NP manifestations in our
patients as reported [1]. Unexpectedly, the frequency of
ischemic stroke in our cohort was similar in the APS+
and APS− groups. The APS− NPSLE group was further
characterized by seizures which were absent in the APS+
group. These were unusual findings and may be due to the
small number of patients. Ischemic stroke occurs frequently
in patients with the APS [48–51], and even though seizures
are not part of the revised classification criteria for APS [26]
they are well described in this entity [52, 53]. Recurrence and
persistence of NP disease occurred exclusively in the APS-
group and in three patients was associated with lupus nephri-
tis. Cumulative mortality was higher in NPSLE patients, in
particular in those with antiphospholipid antibodies and
long disease duration. This finding is in accordance with the
10-year Eurolupus study, where cerebral thrombosis due to
the APS was found to be the leading cause of death in SLE
patients when death occurred after a time lapse of five years
from the initial diagnosis [54].
In summary, we have been unable to find diﬀerentiating
traits that can be used in clinical practice betweenNPSLE and
non-NPSLE patients. Within the NPSLE group of patients,
the group of APS− patients could be distinguished from
the APS positive group by the fact that in the first group,
the NP event occurred almost simultaneously with SLE
diagnosis while in the latter, the event occurred at a much
later time. Recurrence and persistence of NP disease were
only observed in the APS-group of patients, frequently
associated with the recurrence of nephritis. In addition,
overall mortality was higher in NPSLE and APS patients
with inadequate anticoagulation control, identifying an area
that requires improved vigilance and the development of
novel therapeutic modalities. The identification of a higher
frequency of smokers in the NPSLE group deserves further
understanding of the underlying pathogenetic mechanism
and institution of preventative measures.
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